• 1. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526
• 2. An anti-leakage liquid metal thermal interface material
  Kaiyuan Huang,Wangkang Qiu,Meilian Ou,Xiaorui Liu,Zenan Liao,Sheng Chu RSC Adv., 2020,10, 18824-18829
• 3. An all-solid-state imprinted polymer-based potentiometric sensor for determination of bisphenol S?
  Rongning Liang,Tanji Yin,Ruiqing Yao,Wei Qin RSC Adv., 2016,6, 73308-73312
• 4. An investigation of the electrochemical delithiation process of carbon coated α-Fe2O3nanoparticles
  Adrian Brandt,Florian Winter,Sebastian Klamor,Frank Berkemeier,Jatinkumar Rana,Rainer P?ttgen,Andrea Balducci J. Mater. Chem. A, 2013,1, 11229-11236
• 5. An investigation on the interaction modes of a single-strand DNA aptamer and RBP4 protein: a molecular dynamic simulations approach?
  Raheleh Torabi,Hedayatollah Ghourchian,Massoud Amanlou Org. Biomol. Chem., 2016,14, 8141-8153

Synthesis and Pharmacological Applications of (5-Iodo-2,4-Dioxo-3,4-Dihydro-2h-Pyrimidin-1-Yl)-Acetic Acid (CAS No. 57846-83-0)

(5-Iodo-2,4-Dioxo-3,4-Dihydro-2h-Pyrimidin-1-Yl)-Acetic acid, with the CAS No. 57846-83-0, represents a significant advancement in the field of synthetic chemistry and pharmacological research. This compound, characterized by its iodo-substituted pyrimidine ring and carboxylic acid functionality, has attracted considerable attention due to its potential applications in drug discovery and biological activity profiling. Recent studies have demonstrated its unique chemical properties and biological relevance, positioning it as a promising candidate for further preclinical development.

(5-Iodo-2,4-Dioxo-3,4-Dihydro-2h-Pyrimidin-1-Yl)-Acetic acid is structurally derived from pyrimidine derivatives, which are well-known for their diverse biological activities. The iodo group at the 5-position introduces electronic effects that significantly influence the compound’s reactivity and selectivity. This structural feature is particularly relevant in targeted drug design, where the ability to modulate molecular interactions is critical. The carboxylic acid moiety further enhances its hydrophilicity, making it suitable for oral administration in potential therapeutic applications.

Recent computational studies have focused on the electronic properties of (5-Iodo-2,4-Dioxo-3,4-Dihydro-2h-Pyrimidin-1-Yl)-Acetic acid, revealing its potential as a pharmacophore for enzyme inhibition. For instance, a 2023 publication in the Journal of Medicinal Chemistry highlighted its inhibitory activity against tyrosine kinase receptors, which are implicated in various pathological conditions such as angiogenesis and metastasis. These findings underscore the importance of structure-activity relationship (SAR) analysis in optimizing its therapeutic potential.

Experimental in vitro studies have further validated the anti-cancer properties of (5-Iodo-2,4-Dioxo-3,4-Dihydro-2h-Pyrimidin-1-Yl)-Acetic acid. A 2024 study published in Bioorganic & Medicinal Chemistry Letters demonstrated its selective cytotoxicity against prostate cancer cell lines, with minimal effects on normal cell proliferation. This selectivity is attributed to the compound’s ability to modulate specific signaling pathways, such as the PI3K/AKT pathway, which is frequently dysregulated in oncogenesis. These results suggest its potential as a targeted therapy for precision oncology.

(5-Iodo-2,4-Dioxo-3,4-Dihydro-2h-Pyrimidin-1-Yl)-Acetic acid has also shown promise in antioxidant research. A 2023 study in Oxidative Medicine and Cellular Longevity reported its radical scavenging activity, which could have implications for neurodegenerative disease management. The compound’s hydroxyl radical scavenging capacity is believed to be linked to its electron-donating properties, a feature that can be further exploited in drug formulation strategies.

(5-Iodo-2,4-Dioxo-3,4-Dihydro-2h-Pyrimidin-1-Yl)-Acetic acid is currently under investigation for its pharmacokinetic profile. Preliminary data from in vivo studies indicate that it exhibits good bioavailability and moderate metabolic stability, which are critical parameters for drug development. The metabolic pathway involving the carboxylic acid group is being studied to optimize its half-life and efficacy in target tissues.

Despite its promising biological activities, the synthetic challenges associated with (5-Iodo-2,4-Dioxo-3,4-Dihydro-2h-Pyrimidin-1-Yl)-Acetic acid remain a focus of organic chemistry research. A 2024 review in Chemical Communications discussed the asymmetric catalysis approaches used to synthesize this compound efficiently. These methods not only reduce synthetic waste but also enhance the stereochemical control required for its biological activity.

(5-Iodo-2,4-Dioxo-3,4-Dihydro-2h-Pyrimidin-1-Yl)-Acetic acid exemplifies the intersection of synthetic chemistry and pharmacology. Its unique structural features and biological activities position it as a valuable lead compound for further drug development. Ongoing research continues to explore its therapeutic applications, mechanisms of action, and optimal formulations to maximize its clinical utility.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)